The deadline for submission of offers is extended to 10 February 2023.

This call concerns diagnostic and testing solutions addressing threats that are relevant for HERA, i.e. serious cross border threats to health as defined in Regulation (EU) 2022/2371. This includes communicable diseases, including those of zoonotic origin and antimicrobial resistance. While the call targets primarily solutions allowing for the identification or characterisation of a pathogen present in a patient, “companion diagnostics” (in vitro diagnostic test that supports the safe and effective use of a specific medicinal product by identifying patients that are suitable or unsuitable for treatment) will also be considered, as long as they address serious cross border threats to health.